Publications by authors named "Pascal Joly"

Claim this Profile
C
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review.
Billal Tedbirt, Eva W H Korte, Marjolein A J Hiel, Joost M Meijer, Maria C Bolling, Pascal Joly

Clin Drug Investig· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab as a potential therapeutic agent in bullous pemphigoid: a biologic and clinical proof-of-concept study.
Vlada Koliadenko, Pascal Joly, Flora Lemaire, Saskia Ingen-Housz-Oro, Christophe Bedane

Br J Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bullous Pemphigoid Outcome Measurement: A Scoping Review of Outcome Heterogeneity and Trends in Clinical Research of Treatments.
Marjolein A J Hiel, Billal Tedbirt, Eva W H Korte, Maria C Bolling, Joost M Meijer, Pascal Joly

Br J Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the efficacy and safety of dapsone alone or associated with topical corticosteroids for pemphigus foliaceus: a retrospective multicentre study.
Sofia Tzoumpa, Gérôme Bohelay, Saskia Ingen-Housz-Oro, Emmanuelle Tancrède-Bohin, Vanina Seta, Pascal Joly

Br J Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of upadacitinib in patients with severe alopecia areata, including baricitinib-refractory cases: A case series of 22 patients.
Fjola Chambres, Florence Tétart, Raphael Janela-Lapert, Hélène Aubert, Fbienne-Nadia Raison-Peyron, Pascal Joly

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ.
Chloé Paris, Raphaëlle Curmin, Laurie Gouillon, Caroline Giboin, Yann De Rycke, Pascal Joly

J Eur Acad Dermatol Venereol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions.
Marjolein A J Hiel, Eva W H Korte, Billal Tedbirt, Marieke C Bolling, Joost M Meijer, Pascal Joly

Br J Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: Evaluation from the French healthcare system.
Billal Tedbirt, Hermance De Mulder, Pascal Joly, Elie Lacroix, Vivien Hébert

J Eur Acad Dermatol Venereol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting Report on "10th Anniversary Symposium on Inflammatory Skin Disease".
Shirin Emtenani, John F Baines, Katja Bieber, Evelyn Gaffal, Stephanie Goletz, Pascal Joly

JID Innov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.
Maud Maho-Vaillant, Alexandre Lemieux, Christophe Arnoult, Léopoldine Lebourgeois, Vivien Hébert, Pascal Joly

Br J Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors.
Vivien Hébert, Sami Hamwi, Emmanuelle Tancrède-Bohin, Gaelle Quéreux, Anne Pham-Ledard, Pascal Joly

JAMA Dermatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.
Billal Tedbirt, Estelle Houivet, Maud Maho-Vaillant, Marie-Laure Golinski, Sébastien Calbo, Pascal Joly

JAMA Dermatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of virtual reality on pain and anxiety management in dermatological procedures.
Jeanne Guillet, Billal Tedbirt, Vivien Hebert, Charlotte Emonet, André Gilibert, Pascal Joly

J Eur Acad Dermatol Venereol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece.
Meropi Karakioulaki, Patrick Dunn, Dedee F Murrell, Aimee Payne, Enno Schmidt, Pascal Joly

JID Innov· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Bullous pemphigoid.
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, Yen Loo Lim, Anisa Mosam, Pascal Joly

Nat Rev Dis Primers· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The need to prevent corticosteroid-induced myopathy in patients with autoimmune bullous skin diseases.
Pascal Joly

J Eur Acad Dermatol Venereol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bullous pemphigoid.
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, Yen Loo Lim, Anisa Mosam, Pascal Joly

Nat Rev Dis Primers· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Alizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, Michel D'Incan, Gaëlle Quereux, Pascal Joly

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review).
Victoria P Werth, Dédée F Murrell, Pascal Joly, Renata Heck, Jamie M Orengo

Adv Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemphigoid gestationis is associated with an increased risk for adverse pregnancy outcomes: A large-scale propensity-matched retrospective cohort study.
Sophie L Preuß, Artem Vorobyev, Eva Lotta Moderegger, Patrick Terheyden, Katja Bieber, Pascal Joly

J Am Acad Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.
Vivien Hébert, Julien Novarino, Maud Maho-Vaillant, Corine Perals, Sébastien Calbo, Pascal Joly

Br J Dermatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database.
Laurent Mortier, Astrid Blom, Benoît van Hille, Mahtab Samimi, Laura Luciani, Pascal Joly

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab.
Camélia Benhayoun, Anne Bénédicte Duval Modeste, Clémence Tamarit, Pascal Joly, Raphaël Janela-Lapert

JAAD Case Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Alizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, Michel D'Incan, Gaëlle Quereux, Pascal Joly

EClinicalMedicine· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis